BioScrip Inc (NASDAQ:BIOS) – Research analysts at SunTrust Banks dropped their Q1 2019 earnings per share (EPS) estimates for shares of BioScrip in a report issued on Monday, March 18th. SunTrust Banks analyst D. Macdonald now expects that the company will earn ($0.09) per share for the quarter, down from their previous forecast of ($0.07). SunTrust Banks also issued estimates for BioScrip’s Q2 2019 earnings at ($0.06) EPS, Q4 2019 earnings at ($0.03) EPS, FY2019 earnings at ($0.22) EPS and FY2020 earnings at ($0.17) EPS.

Several other research firms have also commented on BIOS. BidaskClub upgraded BioScrip from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, November 28th. Canaccord Genuity initiated coverage on BioScrip in a research report on Wednesday, December 12th. They issued a “buy” rating and a $5.00 price target for the company. TheStreet raised shares of BioScrip from a “d+” rating to a “c-” rating in a research note on Monday, November 26th. Lake Street Capital raised their price objective on shares of BioScrip from $4.50 to $10.00 and gave the stock a “buy” rating in a research note on Friday, December 7th. Finally, Zacks Investment Research downgraded shares of BioScrip from a “hold” rating to a “sell” rating in a research note on Thursday, January 3rd. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $4.70.

BIOS opened at $2.14 on Thursday. The stock has a market capitalization of $308.85 million, a P/E ratio of -4.37 and a beta of 0.76. BioScrip has a 12 month low of $2.13 and a 12 month high of $4.14.

BioScrip (NASDAQ:BIOS) last released its quarterly earnings results on Friday, March 15th. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.11). The company had revenue of $183.57 million during the quarter, compared to the consensus estimate of $188.39 million. The company’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.03) EPS.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Maven Securities LTD bought a new stake in BioScrip in the fourth quarter worth about $45,000. Caxton Associates LP bought a new stake in BioScrip in the fourth quarter worth about $52,000. Virtu Financial LLC lifted its stake in BioScrip by 60.6% in the fourth quarter. Virtu Financial LLC now owns 18,208 shares of the company’s stock worth $65,000 after purchasing an additional 6,868 shares during the last quarter. Menta Capital LLC bought a new stake in BioScrip in the fourth quarter worth about $124,000. Finally, Engineers Gate Manager LP bought a new stake in BioScrip in the third quarter worth about $146,000. 82.58% of the stock is owned by institutional investors and hedge funds.

About BioScrip

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

Read More: What are gap-up stocks?

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.